Stock DVAX DYNAVAX TECHNOLOGIES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Dynavax Technologies Corporation

Equities

DVAX

US2681582019

Market Closed - Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		5-day change 1st Jan Change
11.65 USD -0.94% Intraday chart for Dynavax Technologies Corporation -0.26% -16.67%
05-08 Transcript : Dynavax Technologies Corporation, Q1 2024 Earnings Call, May 08, 2024
05-08 Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M
MT
Dynavax Technologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue
MT
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q4 Revenue $55.6M, vs. Street Est of $52.7M
MT
Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024
CI
Dynavax Technologies Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q3 Revenue $69.5M, vs. Street Est of $61.4M
MT
Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023
CI
Dynavax Technologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Dynavax Technologies Corporation Raises Revenue Guidance for the Full Year 2023
CI
Dynavax Technologies Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q2 Revenue $60.2M
MT
Dynavax Technologies Swings to Q1 Loss, Revenue Declines
MT
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q1 Revenue $46.9M, vs. Street Est of $38.6M
MT
Dynavax Technologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023
CI
Dynavax Says it Obtained Great Britain Marketing Authorization for Heplisav Hepatitis B Vaccine
MT
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine
CI
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DVAX Stock
  4. News Dynavax Technologies Corporation
  5. Highlights